{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-24-000093","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.380346+00:00","generated_at":"2026-05-30T03:40:02.503987+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Gossamer Bio Q3 net loss $30.8M; cash $327M, runway into H1 2027","bullets":["Net loss of $30.8M ($0.14/share) vs $40.0M ($0.21/share) in Q3 2023; revenue from Chiesi collaboration was $9.5M.","Cash, cash equivalents & marketable securities $327M as of Sept 30, 2024; expected to fund operations into H1 2027.","Phase 3 PROSERA trial in PAH enrollment ongoing; topline results expected Q4 2025.","Expect to commence global registrational Phase 3 trial for PH-ILD in mid-2025.","R&D expenses $34.9M (up from $31.2M); G&A $8.5M (down from $9.3M) YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-24-000093","json":"https://secwatch.observer/filing/0001728117-24-000093.json","markdown":"https://secwatch.observer/filing/0001728117-24-000093.md","text":"https://secwatch.observer/filing/0001728117-24-000093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811724000093/0001728117-24-000093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811724000093/goss-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:40:02.503987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}